Implementation Science
Effectiveness
Feasibility & Acceptability
Cost-Effectiveness
In 2020 an estimated 9.9 million people fell ill with TB, and 1.5 million people died from TB.
The Triage Test for All Oral DR-TB Regimen (TRiAD) is a multi-centre, multi-country operational study funded by the European and Developing Countries Clinical Trials Partnership (EDCTP) funded over 4 years which commenced on January 2021 This operational study aims to assess the effectiveness, feasibility, acceptability, and cost effectiveness of the GeneXpert MTB/XDR (Xpert XDR; Cepheid) assay for rapid triage-and-treatment of Drug Resistance TB (DR-TB).
read more
The consortium coordinator, Professor Kogieleum Naidoo, will provide overall leadership, clinical management, and oversight of the entire study. She has over 20 years of experience in clinical research and has conducted several large clinical trials. She will be responsible for the conduct of this trial.
“Our aim is to evaluate the effectiveness, operational feasibility, acceptability, and cost-effectiveness of implementing the Xpert MTB/XDR for rapid triage and selection of all-oral regimens for DR-TB”
Professor Kogie Naidoo, National Principal Investigator of TRiAD
